BioCorRx Inc. (BICX)
OTCMKTS · Delayed Price · Currency is USD
0.4780
+0.0480 (11.16%)
Aug 1, 2025, 12:11 PM EDT
Intra-Cellular Therapies Revenue
BioCorRx had revenue of $134.90K in the quarter ending March 31, 2025, with 3,626.49% growth. This brings the company's revenue in the last twelve months to $138.94K, up 165.47% year-over-year. In the year 2024, BioCorRx had annual revenue of $7.67K, down -91.40%.
Revenue (ttm)
138.94K
Revenue Growth
+165.47%
P/S Ratio
59.45
Revenue / Employee
46.31K
Employees
3
Market Cap
8.26M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.67K | -81.50K | -91.40% |
| Dec 31, 2023 | 89.16K | -124.68K | -58.31% |
| Dec 31, 2022 | 213.84K | 165.57K | 342.99% |
| Dec 31, 2021 | 48.27K | -74.35K | -60.63% |
| Dec 31, 2020 | 122.62K | -117.64K | -48.96% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo, Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 84.04M |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.70M |
BioCorRx News
- 1 year ago - BioCorRx GAAP EPS of -$0.13, revenue of $4.04M - Seeking Alpha
- 1 year ago - BioCorRx Reports Business Update for the Second Quarter of 2024 - GlobeNewsWire
- 1 year ago - BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia - GlobeNewsWire
- 1 year ago - BioCorRx Reports Business Update for 2023 - GlobeNewsWire
- 1 year ago - BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD - GlobeNewsWire
- 1 year ago - BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors - GlobeNewsWire
- 1 year ago - BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President - GlobeNewsWire
- 1 year ago - BioCorRx Reports Business Update for the Third Quarter of 2023 - GlobeNewsWire